Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats

Brain Research

Volumn 972, Issue 1-2, 2003, Pages 229-234

  Arai, Akira ^a   Kannari, Kazuya ^a   Shen, Huo ^a   Maeda, Tetsuya ^a   Suda, Toshihiro ^a   Matsunaga, Muneo ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Amantadine; Aromatic L amino acid decarboxylase; Dopamine; L DOPA; Parkinson's disease; Striatum

Indexed keywords

AMANTADINE; AMINO ACID DECARBOXYLASE; BENSERAZIDE; DOPAMINE; LEVODOPA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRIATONIGRAL DEGENERATION;

EID: 0242669954     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02531-9     Document Type: Article

References (34)

1. Arai R., Karasawa N., Nagatsu I. Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res. 706:1996;177-179.
2. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997;447-453.
3. Classical transmitters in the CNS. Bjorklund A., Hökfelt T. Part 1: Handbook of Chemical Neuroanatomy. Vol. 2:1984;23-54 Elsevier, Amsterdam.
4. Butzer J.F., Silver D.E., Sahs A.L. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 25:1975;603-606.
5. Deep P., Dagher A., Sadikot A., Gjedde A., Cumming P. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse. 34:1999;313-318.
6. Finkelstein D.I., Stanic D., Parish C.L., Tomas D., Dickson K., Horne M.K. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience. 97:2000;99-112.
7. Fisher A., Biggs C.S., Starr M.S. Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat. Brain Res. 792:1998;126-132.
8. Fletcher E.A., Redfern P.H. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J. Pharm. Pharmacol. 22:1970;957-959.
9. Fredriksson A., Danysz W., Quack G., Archer T. Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice. J. Neural Transm. 108:2001;167-187.
10. Giros B., Wang Y.M., Suter S., McLeskey S.B., Pifl C., Caron M.G. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 269:1994;15985-15988.
11. Karcz-Kubicha M., Quack G., Danysz W. Amantadine attenuates response alterations resulting from repetitive L-DOPA treatment in rats. J. Neural Transm. Suppl. 105:1998;1229-1236.
12. Kornhuber J., Bormann J., Hubers M., Rusche K., Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. 206:1991;297-300.
13. Li X.M., Juorio A.V., Qi J., Boulton A.A. Amantadine increases aromatic L-amino acid decarboxylase mRNA in PC12 cells. J. Neurosci. Res. 53:1998;490-493.
14. Mann D.C., Pearce L.A., Waterbury L.D. Amantadine for Parkinson's disease. Neurology. 21:1971;958-962.
15. Mizoguchi K., Yokoo H., Yoshida M., Tanaka T., Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res. 662:1994;255-258.
16. Nagatsu T., Yamamoto T., Kato K. A new and highly sensitive voltammetric assay for aromatic L-amino acid decarboxylase activity by high-performance liquid chromatography. Anal. Biochem. 100:1979;160-165.
17. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 56:2001;S1-S88.
18. Pacholczyk T., Blakely R.D., Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 350:1991;350-354.
19. Parkes J.D., Baxter R.C., Curzon G., Knill-Jones R.P., Knott P.J., Marsden C.D., Tattersall R., Vollum D. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study. Lancet. i:1971;1083-1086.
20. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, London.
21. Quack G., Hesselink M., Danysz W., Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J. Neural Transm. Suppl. 46:1995;97-105.
22. Rabey J.M., Nissipeanu P., Korczyn A.D. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 4:1992;277-282.
23. Schwab R.S., Poskanzer D.C., England A.C. Jr., Young R.R. Amantadine in Parkinson's disease. Review of more than two years' experience. J. Am. Med. Assoc. 222:1972;792-795.
24. Shannon K.M., Goetz C.G., Carroll V.S., Tanner C.M., Klawans H.L. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin. Neuropharmacol. 10:1987;522-526.
25. Skuza G., Rogoz Z., Quack G., Danysz W. Memantine, amantadine, and L-deprenyl potentiate the action of L-dopa in monoamine-depleted rats. J. Neural Transm. Gen. Sect. 98:1994;57-67.
26. Stoof J.C., Booij J., Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications. Clin. Neurol. Neurosurg. 94:(Suppl.):1992;S4-6.
27. Stoof J.C., Booij J., Drukarch B., Wolters E.C. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur. J. Pharmacol. 213:1992;439-443.
28. Takahashi T., Yamashita H., Zhang Y.X., Nakamura S. Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res. Bull. 41:1996;363-367.
29. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 10:1999;631-634.
30. Timberlake W.H., Vance M.A. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann. Neurol. 3:1978;119-128.
31. Verhagen Metman L., Del Dotto O., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
32. Vernier V.G., Harmon J.B., Stump J.M., Lynes T.E., Marvel J.P., Smith D.H. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol. Appl. Pharmacol. 15:1969;642-665.
33. Von Voigtlander P.F., Moore K.E. Dopamine: release from the brain in vivo by amantadine. Science. 174:1971;408-410.
34. Zhou F.C., Bledsoe S., Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556:1991;108-116.